Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasion

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 6, 2008, Pages 949-957

  Xie, Zhigang ^a   Choong, Pei Feng ^a   Poon, Lai Fong ^a   Zhou, Jianbiao ^a   Khng, Jiaying ^a   Jasinghe, Viraj Janakakumara ^a   Palaniyandi, Senthilnathan ^a   Chen, Chien Shing ^a,b,c  

^a Dept Medicine Endocrinol Diabet   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c LOMA LINDA UNIVERSITY   (United States)

Author keywords

Antisense oligonucleotides; CD44 antigen; Chemotherapy; Hepatocellular carcinoma

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; D 1515; DOXORUBICIN; HERMES ANTIGEN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CARCINOGENESIS; CELL ASSAY; CELL DEATH; CELL VIABILITY; CHEMOSENSITIVITY; COLONY FORMATION; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTIGENS, CD44; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; LIVER NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; RNA, NEOPLASM; TRANSFECTION; TUMOR STEM CELL ASSAY;

EID: 51849111187     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0684-z     Document Type: Article

References (43)

1. JM Llovet M Beaugrand 2003 Hepatocellular carcinoma: present status and future prospects J Hepatol 38 S136 S149
2. J Bruix L Boix M Sala JM Llovet 2004 Focus on hepatocellular carcinoma Cancer Cell 5 215 219
3. TF Greten F Papendorf JS Bleck T Kirchhoff T Wohlberedt S Kubicka 2005 Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients Br J Cancer 92 1862 1868
4. MA Avila C Berasain B Sangro J Prieto 2006 New therapies for hepatocellular carcinoma Oncogene 25 3866 3884
5. TF Greten MP Manns F Korangy 2006 Immunotherapy of hepatocellular carcinoma J Hepatol 45 868 878
6. GK Abou-Alfa 2006 Hepatocellular carcinoma: molecular biology and therapy Semin Oncol 33 S79 S83
7. AX Zhu 2007 Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma Cancer 112 250 259
8. LJ Bendall SK Nilsson NI Khan A James C Bonnet RB Lock 2004 Role of CD44 variant exon 6 in acute lymphoblastic leukemia: association with altered bone marrow localisation and increased tumour burden Leukemia 18 1308 1311
9. H Ponta L Sherman PA Herrlich 2003 CD44: from adhesion molecules to signalling regulators Nat Rev Mol Cell Biol 4 33 45
10. DL Cooper GJ Dougherty 1995 To metastasize or not? Selection of CD44 splice sites Nat Med 1 635 637
11. J Liu G Jiang 2006 CD44 and hematologic malignancies Cell Mol Immunol 3 359 365
12. D Naor S Nedvetzki I Golan L Melnik Y Faitelson 2002 CD44 in cancer Crit Rev Clin Lab Sci 39 527 579
13. S Jothy 2003 CD44 and its partners in metastasis Clin Exp Metastasis 20 195 201
14. S Seiter D Schadendorf K Herrmann M Schneider M Rosel R Arch 1996 Expression of CD44 variant isoforms in malignant melanoma Clin Cancer Res 2 447 456
15. E Akisik S Bavbek N Dalay 2002 CD44 variant exons in leukemia and lymphoma Pathol Oncol Res 8 36 40
16. K Endo T Terada 2000 Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival J Hepatol 32 78 84
17. L Jin KJ Hope Q Zhai F Smadja-Joffe JE Dick 2006 Targeting of CD44 eradicates human acute myeloid leukemic stem cells Nat Med 12 1167 1174
18. G Song X Liao L Zhou L Wu Y Feng ZC Han 2004 HI44a, an anti-CD44 monoclonal antibody, induces differentiation and apoptosis of human acute myeloid leukemia cells Leuk Res 28 1089 1096
19. Z Gadhoum J Delaunay E Maquarre L Durand V Lancereaux J Qi 2004 The effect of anti-CD44 monoclonal antibodies on differentiation and proliferation of human acute myeloid leukemia cells Leuk Lymphoma 45 1501 1510
20. RS Charrad Z Gadhoum J Qi A Glachant M Allouche C Jasmin 2002 Effects of anti-CD44 monoclonal antibodies on differentiation and apoptosis of human myeloid leukemia cell lines Blood 99 290 299
21. I Tamm B Dörken G Hartmann 2001 Antisense therapy in oncology: new hope for an old idea? Lancet 358 489 497
22. M Spitaler B Wiesenhofer V Biedermann T Seppi J Zimmermann H Grunicke 1999 The involvement of protein kinase C isoenzymes alpha, epsilon and zeta in the sensitivity to antitumor treatment and apoptosis induction Anticancer Res 19 3969 3976
23. M Beeram A Patnaik EK Rowinsky 2005 Raf: a strategic target for therapeutic development against cancer J Clin Oncol 23 6771 6790
24. C Bartholomeusz H Itamochi LX Yuan FJ Esteva CG Wood N Terakawa 2005 Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model Cancer Res 65 8406 8413
25. J Lacy R Loomis S Grill P Srimatkandada R Carbone YC Cheng 2006 Systemic Bcl-2 antisense oligodeoxynucleotide in combination with cisplatin cures EBV+ nasopharyngeal carcinoma xenografts in SCID mice Int J Cancer 119 309 316
26. M De Cesare P Perego SC Righetti G Pratesi N Carenini L Rivoltini 2005 Enhanced antitumour efficacy of gimatecan in combination with Bcl-2 antisense oligonucleotide in human melanoma xenografts Eur J Cancer 41 1213 1222
27. LV July E Beraldi A So L Fazli K Evans JC English ME Gleave 2004 Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo Mol Cancer Ther 3 223 232
28. R Kim M Emi K Tanabe T Toge 2004 Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy Cancer 101 2491 2502
29. OA O'Connor EA Smith LE Toner J Teruya-Feldstein S Frankel M Rolfe 2006 The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide Clin Cancer Res 12 2902 2911
30. KM Bullard HR Kim MA Wheeler CM Wilson CL Neudauer MA Simpson 2003 Hyaluronan synthase-3 is upregulated in metastatic colon carcinoma cells and manipulation of expression alters matrix retention and cellular growth Int J Cancer 107 739 746
31. DC Dartsch A Schaefer S Boldt W Kolch H Marquardt 2002 Comparison of anthracycline-induced death of human leukemia cells: programmed cell death versus necrosis Apoptosis 7 537 548
32. A Koceva-Chyla M Jedrzejczak J Skierski K Kania Z Jozwiak 2005 Mechanisms of induction of apoptosis by anthraquinone anticancer drugs aclarubicin and mitoxantrone in comparison with doxorubicin: relation to drug cytotoxicity and caspase-3 activation Apoptosis 10 1497 1514
33. GP Gupta J Massague 2006 Cancer metastasis: building a framework Cell 127 679 695
34. B Radotra D McCormick 1997 Glioma invasion in vitro is mediated by CD44-hyaluronan interactions J Pathol 181 434 438
35. JR Knutson J Iida GB Fields JB McCarthy 1996 CD44/chondroitin sulfate proteoglycan and alpha 2 beta 1 integrin mediate human melanoma cell migration on type IV collagen and invasion of basement membranes Mol Biol Cell 7 383 396
36. SV Ambudkar S Dey CA Hrycyna M Ramachandra I Pastan MM Gottesman 1999 Biochemical, cellular, and pharmacological aspects of the multidrug transporter Annu Rev Pharmacol Toxicol 39 361 398
37. BP Toole 2004 Hyaluronan: from extracellular glue to pericellular cue Nat Rev Cancer 4 528 539
38. H Miyake I Hara S Kamidono ME Gleave 2001 Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model Clin Cancer Res 7 4245 4252
39. X Yang F Zheng H Xing Q Gao W Wei Y Lu 2004 Resistance to chemotherapy-induced apoptosis via decreased caspase-3 activity and overexpression of antiapoptotic proteins in ovarian cancer J Cancer Res Clin Oncol 130 423 428
40. MM Mita L Ochoa EK Rowinsky J Kuhn G Schwartz LA Hammond 2006 A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer Ann Oncol 17 313 321
41. LY Bourguignon E Gilad A Brightman F Diedrich P Singleton 2006 Hyaluronan-CD44 interaction with leukemia-associated RhoGEF and epidermal growth factor receptor promotes Rho/Ras co-activation, phospholipase C epsilon-Ca2+ signaling, and cytoskeleton modification in head and neck squamous cell carcinoma cells J Biol Chem 281 14026 14040
42. LY Bourguignon E Gilad K Rothman K Peyrollier 2005 Hyaluronan-CD44 interaction with IQGAP1 promotes Cdc42 and ERK signaling, leading to actin binding, Elk-1/estrogen receptor transcriptional activation, and ovarian cancer progression J Biol Chem 280 11961 11972
43. KE Miletti-Gonzalez S Chen N Muthukumaran GN Saglimbeni X Wu J Yang K Apolito 2005 The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer Cancer Res 65 6660 6667